Primary hyperhidrosis (HH) is a common challenging problem. Different treatment modalities are present with no clear evidence favoring one modality over the others.
Objectives:
To assess and compare the efficacy of aluminum chloride hexahydrate (ACH), oxybutynin chloride, and botulinum toxin type-A (BTX-A) in treating primary focal HH.
Patients and Methods:
Sixty-six patients of both sexes, with primary HH, were equally and randomly divided into 3 groups. Group (A) received a single session of intradermal (BTX-A), Group (B) received topical application of ACH lotion 25% once daily, and Group (C) received oral oxybutynin chloride 10 mg daily for 3 months. The clinical response was assessed using the Hyperhidrosis Severity Scale (HDSS) and the patients were followed up for 6 months.
Results:
The 3 modalities were effective and safe in the treatment of primary HH, but the clinical response was significantly higher in the BTX-A group (81.8% excellent response) compared to the other 2 modalities. The reduction of hyperhidrosis was also maintained for a longer period in the BTX-A group.
Conclusion:
Among the 3 modalities, BTX-A was associated with a higher reduction of HDSS scores. A single session was sufficient; however, pain and high cost are limiting factors.
NawrockiSChaJ. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up. J Am Acad Dermatol. 2019;81(3):657-666.
2.
GordonJRHillSE. Update on pediatric hyperhidrosis. Dermatol Ther. 2013;26(6):452-461.
3.
EstevanFAWoloskerMBWoloskerNPuech-LeaoP. Epidemiologic analysis of prevalence of the hyperhidrosis. An Bras Dermatol. 2017;92(5):630-634.
4.
HornbergerJGrimesKNaumannM, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274-286.
5.
Khademi KalantariKZeinalzadeAKobarfardFNazary MoghadamS. The effect and persistency of 1% aluminum chloride hexahydrate iontophoresis in the treatment of primary palmar hyperhidrosis. Iran J Pharm Res. 2011;10(3):641-645.
6.
CastiglioneLMurariuMBoeriuEEnatescuI. Assessing botulinum toxin effectiveness and quality of life in axillary hyperhidrosis: a one-year prospective study. Diseases. 2024;12(1):15.
7.
DelortSMarchiECorrêaMA. Oxybutynin as an alternative treatment for hyperhidrosis. An Bras Dermatol. 2017;92(2):217-220.
8.
FlanaganKHKingRGlaserDA. Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. J Drugs Dermatol. 2008;7(3):221-227.
9.
RajagopalRMallyaNB. Comparative evaluation of botulinum toxin versus iontophoresis with topical aluminum chloride hexahydrate in treatment of palmar hyperhidrosis. Med J Armed Forces India. 2014;70(3):247-252.
10.
BudamakuntlaLLoganathanEGeorgeARevanthBNSankeerthVSarvjnamurthySA. Comparative study of efficacy and safety of botulinum toxin a injections and subcutaneous curettage in the treatment of axillary hyperhidrosis. J Cutan Aesthet Surg. 2017;10(1):33-39.
11.
SolishNBertucciVDansereauA, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908-923.
12.
TiwariAAbeysekaraAMCokerJBJacobS. Current treatment options for treating primary hyperhidrosis. Eur J Vasc Endovasc Surg. 2004;28(4):453.
13.
WollinaUKaramfilovT. Botulinum toxin A for palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2001;15(6):555-558.
14.
SolomonBAHaymanR. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol. 2000;42(6):1026-1029.
15.
LoweNCampanatiABodokhI, et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol. 2004;151(6):1115-1122.
16.
Vadoud-SeyediJ. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol. 2004;43(12):969-971.
17.
KarlqvistMRosellKRystedtAHymneliusKSwartlingC. Botulinum toxin B in the treatment of craniofacial hyperhidrosis. J Eur Acad Dermatol Venereol. 2014;28(10):1313-1317.
18.
KinkelinIHundMNaumannMHammH. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol. 2000;143(4):824-827.
19.
NicholasRQuddusABakerDM. Treatment of primary craniofacial hyperhidrosis: a systematic review. Am J Clin Dermatol. 2015;16(5):361-370.
20.
OddersonIR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg. 2002;28(6):480-483.
21.
ScamoniSValdattaLFrigoCMaggiulliFCherubinoM. Treatment of primary axillary hyperhidrosis with botulinum toxin type A: our experience in 50 patients from 2007 to 2010. ISRN Dermatol. 2012;2012:702714.
22.
GohCL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol. 1990;29(5):368-370.
ThianboonsongTKanokrungseeSPaichitrojjanaAUdompataikulMKamanamoolNRojhirunsakoolS. Efficacy and tolerability of 20% aluminum sesquichlorohydrate versus 20% aluminum chloride for the treatment of axillary hyperhidrosis: a randomized controlled trial. Dermatol Ther. 2020;33(6):e14354.
25.
EllisHScurrJH. Axillary hyperhidrosis—topical treatment with aluminum chloride hexahydrate. Postgrad Med J. 1979;55(654):868-869.
26.
NawrockiSChaJ. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol. 2019;81(3):669-680.
27.
El-Agamy El-SamadonyAHegabDSEl MaghrabyGMEl-MaadawyIH. Topical oxybutynin 3% gel versus aluminum chloride 15% lotion in treatment of primary focal hyperhidrosis. Dermatol Pract Concept. 2023;13(3):e2023192.
28.
PariserDMBallardA. Topical therapies in hyperhidrosis care. Dermatol Clin. 2014;32(4):485-490.
29.
StrekerMReutherTHagenLKerscherM. Hyperhidrosis plantaris—a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminum chloride. J Dtsch Dermatol Ges. 2012;10(2):115-119.
30.
WoloskerNFaustinoCBda SilvaMFAde CamposJRMKauffmanP. Current treatment options for craniofacial hyperhidrosis. J Vasc Bras. 2020;19:e20190152.
31.
TorchEM. Remission of facial and scalp hyperhidrosis with clonidine hydrochloride and topical aluminum chloride. South Med J. 2000;93(1):68-69.
32.
Del BozJMillan-CayetanoJFBlazquez-SanchezNde TroyaM. Individualized dosing of oral oxybutynin for the treatment of primary focal hyperhidrosis in children and teenagers. Pediatr Dermatol. 2016;33(3):327-331.
33.
CampanatiAGregoriouSKontochristopoulosGOffidaniA. Oxybutynin for the treatment of primary hyperhidrosis: current state of the art. Skin Appendage Disord. 2015;1(1):6-13.
34.
WoloskerNde CamposJRKauffmanP, et al. An alternative to treat palmar hyperhidrosis: use of oxybutynin. Clin Auton Res. 2011;21(6):389-393.
35.
WoloskerNKrutmanMKauffmanPPaulaRPCamposJRPuech-LeaoP. Effectiveness of oxybutynin for treatment of hyperhidrosis in overweight and obese patients. Rev Assoc Med Bras (1992). 2013;59(2):143-147.
36.
SchollhammerMBrenautEMenard-AndivotN, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173(5):1163-1168.
37.
da Silva CostaAJrLeãoLESucciJE, et al. Randomized trial—oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. Clinics (Sao Paulo). 2014;69(2):101-105.
38.
AttallahHSEl-GilanyAHYoussefYEBAbdelshaheedMESharafEFA. Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis. Indian J Dermatol. 2022;67(3):222-227.
39.
ShelleyWBTalaninNYShelleyED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol. 1998;38(2 Pt 1):227-229.
40.
GrunfeldAMurrayCASolishN. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol. 2009;10(2):87-102.
41.
Glent-MadsenLDahlJC. Axillary hyperhidrosis. Local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol. 1988;68(1):87-89.
